2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5903 A non-gene editing approach to generate allogeneic chimeric antigen receptor (CAR)-T cells

Malika Hoekx, Guoxiang Yang2, Li-Chin Yao3, Lydia Sarah Hui Lee, MBBS, MRCP, MRCPath(Haem), PhD4, Martin Pule, PhD5, James Keck, PhD6, Paul Maciocia7
1 University College London, London, United Kingdom
2 The Jackson Laboratory, Sacramento, California, United States
3 The Jackson Laboratory, Sacramento, California, United States
4 University College London, London, United Kingdom
5 University College London, London, United Kingdom
6 The Jackson Laboratory, Sacramento, California, United States
7 University College London, London, United Kingdom

Background

The use of allogeneic chimeric antigen receptor (CAR)-T cells from healthy donors could address many drawbacks of autologous CAR-T cell therapies including time delays, manufacturing failure, poor T cell quality, logistical issues, and high cost. Allogeneic CAR-T cells risk causing graft versus host disease (GvHD), mediated by donor T cell receptor (TCR) recognition of host tissue. They also risk host-mediated rejection, largely mediated by recognition of foreign major histocompatibility complex (MHC)-I molecules on donor cells, limiting persistence and treatment efficacy. Most previous approaches to allogeneic CAR-T cells use gene-editing to delete TCR and/or MHC-I, introducing complexity, cost, and the potential for off-target genotoxicity. This study aims to express CAR and downregulate TCR and MHC-I in a single vector, eliminating the need for gene editing.

 

Methods and Results

A synthetic fusion protein, VHH3-US11, was designed comprising an anti-CD3ε single-domain VHH fused to the N-terminus of US11, a human cytomegalovirus (HCMV) protein that binds MHC-I α-chains and directs them for ubiquitination and proteasomal degradation. Surface expression of TCR and MHC-I on cells transduced with VHH3-US11 was detected by flow cytometry. VHH3-US11 expression led to robust downregulation of both TCR and MHC-I in primary T cells and cell lines, maintained over 14 days.

10-day one-way mixed lymphocyte reactions (MLRs) were performed to evaluate whether VHH3-US11-mediated downregulation of MHC-I and TCR was functionally robust and protective from allo-rejection and GvHD. Allogeneic PBMCs showed significantly lower expansion and HLA-DR expression in response to VHH3-US11 than control T cells. VHH3-US11 T cells showed significantly lower expansion and HLA-DR expression in response to allogeneic PBMCs compared to control T cells. To further assess whether downregulation of MHC-I was functionally robust and protective, VHH3-US11 T2 cells were pulsed with HA-1 peptide and co-cultured with HA-1 TCR-transduced effector cells. Negative control T2 cells were potently lysed in a dose-dependent fashion while VHH3-US11 T2 cells were resistant to lysis to a similar level as positive control T2 cells.

VHH3-US11 was cloned into a γ-retroviral vector encoding the sort-suicide gene RQR8 and anti-CD19 CAR (CAR19). Downregulation of TCR and MHC-I in primary T cells was sustained in this vector and maintained over 14 days and after co-culture with CD19+ targets.

In vitro efficacy was assessed by 48hr co-culture assays with cytokine quantification by ELISA and re-stimulation assays with differentiation and exhaustion profiling by flow cytometry. VHH3-US11 CAR19 cells demonstrated antigen-specific cytotoxicity and IFN-γ secretion comparable to CAR19-only cells, with similar proliferation, differentiation, and exhaustion profiles. In vivo efficacy was assessed using a Nalm6 NSG xenograft stress test model. CAR19-only and VHH3-US11 CAR19 demonstrated comparable tumor regression and overall survival.

In vivo GvHD was assessed in irradiated NSG-SGM3 mice receiving 5×106 purified CAR-T cells with exogenous IL-2. VHH3-US11 CAR19 recipients demonstrated significantly prolonged survival compared to CAR19 recipients (median survival of 44 days v 14 days, p<0.05) with sustained CAR-T expansion but no GvHD until late outgrowth of residual TCR+ cells.

Bulk RNA-sequencing was performed to compare T cells transduced with CAR19-only or VHH3-US11 CAR19. Gene set enrichment analysis revealed upregulation of unfolded protein response (UPR) genes, consistent with increased ERAD flux from VHH3-US11-mediated degradation of MHC-I and TCR. This response was restricted to the adaptive UPR branch—canonical stress sensors and pro-apoptotic effectors were unchanged. No enrichment of T cell dysfunction, exhaustion, or apoptosis signatures was observed.

 

Conclusions

Expression of a VHH3-US11 fusion protein results in simultaneous downregulation of both TCR and MHC-I from a single transgene without gene-editing. MLRs and alloreactive killing assays demonstrate functional loss of TCR and MHC-I, preventing allo-recognition in both directions in vitro. CAR-T cells co-expressing VHH3-US11 are equally functional to CAR19-only cells in vitro and in vivo, and show significant protection from GvHD in vivo. VHH3-US11 expression results in compensatory chaperon upregulation but not pathological ER stress.

Malika Hoekx: No relevant conflicts of interest to declare.